Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BCML vs CBAN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CBAN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 10–0 Matrix Metrics)

CBAN Overall Winner 6-Pillar Tally: BCML 3 – 3 CBAN Matrix Metrics: BCML 0 – 10 CBAN

As of Nov 20, 2026, Colony Bankcorp Inc. (CBAN) is the stronger overall head-to-head candidate over BayCom Corp (BCML) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCML carries a Unified Composite Score of 40.8/100 (SELL) at $29.78 (12.3x Forward P/E, 15.7% operating margin), whereas CBAN carries 44.5/100 (HOLD) at $19.22 (8.0x Forward P/E, 33.4% operating margin).

  • Technical & Structure Timing Caution: BCML trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.1); meanwhile CBAN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BCML vs CBAN
BCML NASDAQ
BayCom Corp Common Stock
State Commercial Banks
$29.78
-0.9% 1D
Market Cap $328.1M
TTM Revenue $92M
Forward P/E 12.3x
Beta / 30D Vol 0.20β · 21% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 42.0 Fund 52.0 Flow 56.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.1 · SMA20: $30.84 · SMA50: $30.73
CBAN NYSE Head-to-Head Winner
Colony Bankcorp Inc.
State Commercial Banks
$19.22
-1.99% 1D
Market Cap $535.3M
TTM Revenue $154M
Forward P/E 8.0x
Beta / 30D Vol 0.39β · 19% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 30.0 Fund 46.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 32
RSI-14: 32.4 · SMA20: $20.23 · SMA50: $20.32

6-Pillar Scorecard Institutional Category Breakdown (BCML 3 – 3 CBAN)

Columns: Metric · BCML · CBAN
1. Valuation Multiples CBAN
Forward P/E 12.3x 8.0x
Trailing P/E 35.8x 10.8x
PEG Ratio 0.99x 2.11x
EV / Revenue 3.5x 3.5x
2. Growth & Scale CBAN
Revenue Growth (YoY) -16.6% +26.0%
Earnings Growth (YoY) -78.2% +50.2%
TTM Revenue (USD) $92M $154M
Market Cap $328.1M $535.3M
3. Profitability & Quality CBAN
Gross Margin 100.0% 100.0%
Operating Margin 15.7% 33.4%
Net Profit Margin 10.0% 24.3%
Return on Equity (ROE) 2.8% 10.8%
4. Balance Sheet & Cash Flow BCML
Cash Generation (TTM) $33M N/A
Cash Flow Margin 35.7% N/A
Net Cash / Leverage $1.8M Net Cash $18.46 Book/Sh · 10.8% ROE
Dividend Yield 3.93% 2.39%
5. Options & Positioning BCML
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 29.2% (2nd %ile) 594.7% (100th %ile)
Put/Call OI Skew 1.09x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BCML
OpEx & R&D Intensity 84.3% of Rev ($77M) 66.6% of Rev ($102M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Banks - Regional Operator Banks - Regional Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BCML (0) vs CBAN (10)
Institutional Metric BCML CBAN Criterion Row Edge
Market Capitalization
Scale
$328.1M $535.3M Larger Scale CBAN
Trailing P/E Ratio
Valuation
35.8x 10.8x Lower Multiple CBAN
Forward P/E Ratio
Valuation
12.3x 8.0x Lower Multiple CBAN
Revenue Growth (YoY)
Growth
-16.6% +26.0% Higher Growth CBAN
Operating Margin (TTM)
Profitability
15.7% 33.4% Higher Margin CBAN
Net Profit Margin
Profitability
10.0% 24.3% Higher Margin CBAN
Return on Equity (ROE)
Capital Efficiency
2.8% 10.8% Higher ROE CBAN
52-Week Range Position
Momentum
32% ($27–$35) 49% ($16–$22) Stronger Trend CBAN
Beta / 30D Volatility
Risk Regime
0.20β · 21% Vol 0.39β · 19% Vol Lower Realized Risk CBAN
Unified Institutional Score
Composite Signal
40.8 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite CBAN
Trailing 12M Revenue (USD)
Operating Scale
$92M $154M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.99x PEG · 3.5x EV/Rev 2.11x PEG · 3.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$33M ($1.8M Net Cash) N/A ($18.46 Book/Sh · 10.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CBAN +1.56 pp
BCML: -6.65% · CBAN: -5.09%
3M Horizon BCML +8.97 pp
BCML: -1.13% · CBAN: -10.1%
6M Horizon CBAN +1.04 pp
BCML: -3.97% · CBAN: -2.93%
1Y Horizon CBAN +11.43 pp
BCML: +7.51% · CBAN: +18.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCML vs CBAN. Trailing 12-month operating profitability (BCML 15.7% vs CBAN 33.4%) and valuation multiples (BCML 12.3x vs CBAN 8.0x Forward P/E) are benchmarked directly in Pillar 4 below.

BCML ADR TTM Benchmark FX-Normalized USD
TTM Revenue$92M
Gross Margin100.0%
Op. Margin15.7%
ROE / Fwd P/E2.8% · 12.3x
CBAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$154M
Gross Margin100.0%
Op. Margin33.4%
ROE / Fwd P/E10.8% · 8.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BCML CONSOLIDATION
90d in phase · OBV DISTRIBUTION
Current IV 29.2%
IV Percentile 2nd %ile
Put/Call OI Skew 1.09x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BCML Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CBAN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 594.7%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CBAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BCML Moat Profile Scale & Operating Efficiency Moat
Banks - Regional Operator
Competes within the Banks - Regional value chain with $328.1M market capitalization and 15.7% operating margin.
OpEx & R&D Reinvestment 84.3% of Rev ($77M)
90D Engineering Disclosures 0 Published
CBAN Moat Profile High-Margin Pricing Power Moat
Banks - Regional Operator
Competes within the Banks - Regional value chain with $535.3M market capitalization and 33.4% operating margin.
OpEx & R&D Reinvestment 66.6% of Rev ($102M)
90D Engineering Disclosures 0 Published

Investor FAQ BCML vs CBAN Key Questions & Quantitative Answers

As of Nov 20, 2026, Colony Bankcorp Inc. (CBAN) is the stronger overall head-to-head candidate over BayCom Corp (BCML) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCML carries a Unified Composite Score of 40.8/100 (SELL) at $29.78 (12.3x Forward P/E, 15.7% operating margin), whereas CBAN carries 44.5/100 (HOLD) at $19.22 (8.0x Forward P/E, 33.4% operating margin). Technical & Structure Timing Caution: BCML trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.1); meanwhile CBAN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CBAN leads the Growth & Scale pillar: BCML posts -16.6% YoY revenue growth and -78.2% YoY earnings growth on $92M TTM revenue (100.0% gross margin, 15.7% operating margin), compared with CBAN at +26.0% YoY revenue growth and +50.2% YoY earnings growth on $154M TTM revenue (100.0% gross margin, 33.4% operating margin). On trailing 12-month operating scale, BCML generates $92M in USD-normalized revenue versus $154M for CBAN. In operating R&D and SG&A reinvestment, BCML deploys 84.3% of Rev ($77M) (0 90-day corporate R&D disclosures) versus 66.6% of Rev ($102M) (0 disclosures) for CBAN.

CBAN screens cheaper on headline valuation multiples. BCML trades at 12.3x Forward P/E, 35.8x Trailing P/E, 0.99x PEG, and 3.5x EV/Revenue (35.7% FCF margin), whereas CBAN trades at 8.0x Forward P/E, 10.8x Trailing P/E, 2.11x PEG, and 3.5x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCML (2.8% ROE) versus CBAN (10.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BCML carries 29.2% implied volatility (2nd %ile, Compressed (<25th %ile)), a 1.09x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.20β · 21% Vol realized risk). By comparison, CBAN carries 594.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 19% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.